GeneReach Biotechnology Corp. (4171) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for GeneReach Biotechnology Corp. (4171:TWSE), powered by AI.

Current Price
$17.40
Sector
Healthcare
What is the GeneReach Biotechnology Corp. stock price forecast?

GeneReach Biotechnology Corp. is currently trading at $17.40. View real-time AI analysis on Alpha Lenz.

What is GeneReach Biotechnology Corp. insider trading activity?

View the latest insider trading data for GeneReach Biotechnology Corp. on Alpha Lenz.

What is GeneReach Biotechnology Corp.'s P/E ratio?

View GeneReach Biotechnology Corp.'s valuation metrics on Alpha Lenz.

GeneReach Biotechnology Corp.

TWSE · 4171
NT$17.40-0.05(-0.29%)
Ask about GeneReach Biotechnology Corp.'s future dividend policy...
Alpha Chat Insight

GeneReach Biotechnology Corp.'s ROE is -16.9%. Explore profitability and growth together.

Ask for details

Company Overview

GeneReach Biotechnology Corp. is a biotechnology company specializing in the development, manufacturing, and marketing of applied nucleic acid detection technologies. Its primary purpose is to provide advanced diagnostic solutions across a spectrum of industries, focusing on pathogen detection platforms that include automatic nucleic acid extraction systems, polymerase chain reaction (PCR) detection equipment, and a range of specialized reagents and consumables. The company serves diverse sectors such as aquaculture, agriculture, food safety, human and animal health—delivering products that support disease management, prevention, and research applications. GeneReach Biotechnology Corp. is recognized for ensuring quality standards, with manufacturing processes that comply with ISO 13485 and Good Manufacturing Practices. Since its founding in 2004, the company has played a significant role in enabling faster, reliable, and accessible molecular diagnostics, supporting both large-scale industry and smaller point-of-care environments. Its work not only advances health management in Taiwan but also contributes to global health innovation by offering OEM/ODM services, research collaborations, and technical solutions to its partners and clients worldwide.

SectorHealthcare
IndustryBiotechnology
0

Company Statistics

FY 2025

Profile

N/AMarket Cap
NT$232.74MRevenue
0.00Shares Out
0Employees

Margins

69.14%Gross
-19.73%EBITDA
-37.34%Operating
-50.04%Pre-Tax
-48.52%Net

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

-32.30%Rev 3Yr
-22.95%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-11.60%ROA
-16.92%ROE
-11.29%ROIC

Financial Health

NT$155.07MCash & Cash Equivalents
NT$129.27MNet Debt
47.65%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

GeneReach Biotechnology Corp. (ticker: 4171) is a company listed on TWSE in the Healthcare sector (Biotechnology).

The current price is 17.4 with a P/E ratio of -x and P/B of -x.

ROE is -16.92% and operating margin is -37.34%. Annual revenue is $233M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
GeneReach Biotechnology Corp. (4171) Stock Forecast 2026 $17.40 — Price, Financials & Analyst Targets | Alpha Lenz